Life Sciences Connect

Europe faces substantial challenges in continuing to deliver high-quality healthcare services to its citizens. With growing populations, rigid financing models and rising health inequalities, the conventional, reactive 'sick care' model needs to move to a more proactive, preventative and participatory model of care. Without this transition, by 2040, European healthcare services will face being ove...

In episode 27 of the Life Sciences Connect Podcast, we speak to the authors of the Time to Change report and discuss the current state of the UK healthcare workforce, touching on topics including pay, diversity, work-life balance, and training.   During our conversation, we explore the unrelenting challenges facing the UK's healthcare workforce and share actionable, evidence-based solutions to hel...

In Episode 26, our panel of industry experts dive into the key trends and challenges facing the consumer health industry. This is one not to miss. With increased access to information, greater levels of choice and improved functionality of products and technology, consumers are increasingly taking a more proactive role in managing their own health. Tune in for our expert panel's views on the futur...

Tune in to the latest episode of the  Life Sciences Connect  podcast, where you will find Sara Siegel's fireside chat about all things Global Healthcare Episode 25 welcomes the new Global Head of Health and previous guest, Sara Siegel who discusses with Karen the various challenges impacting global healthcare systems today, their hopes and ambitions for the future.

Karen and the team explore the findings from the Future of Diagnostic Series    Episode 24 podcast explores some of the themes highlighted in our two reports on the future of diagnostics and specifically how the adoption of innovation and new models of service delivery are transforming diagnostic imaging. 

Listen to episode twenty-three to hear Karen, and our guests dissect the findings from the latest annual R&D ROI R eport which launched last month. T his report has provided insights into the state of biopharma R&D since 2010. We have expanded the analysis over time and our data set now covers the top 20 pharma companies by R&D spend

In episode twenty-two, we explore the challenges facing UK government and public services. Tune in as our experts discuss the issues currently facing health and social care, from unsustainable levels of funding to longstanding pressures on the workforce. Join Karen Taylor, Ed Roddis and Emma Horrell as they dissect the findings from the latest State of the State report to bring you a view of the s...

On this episode of Life Sciences Connect podcast, we bring the discussion of emission reduction to the forefront. Hear our guest discuss further: James Gregson – UK's Life Sciences & Healthcare industry leader At the start of October we launched our report: Embedding environmental sustainability into pharma's DNA. In this episode of we explore the pressing challenges facing pharma in achieving amb...

On this episode of Life Sciences Connect podcast, we discuss these issues further with our panel of experts: Andy Flockhart , UK MedTech Leader Guido Baechler , CEO of Mainz Biomed And of course, our host, Karen Taylor, Research Director, Centre for Health Solutions, Deloitte Diagnostics play a pivotal role across the entire healthcare continuum from screening, detection and prognosis to patient s...

Episode 19 of the Life Sciences Connect podcast sheds light on the important topic of Health equity and dives into discussions around what this really means, what businesses can do to improve this, how diversity groups are affected and much more. To learn more about health equity and other important issues facing public health in the UK, explore out Future of Public Health Series

Listen to episode 18 of the Life Sciences Connect podcast where we talk to specialists about Hospital Activation, how we are breaking from the traditional approach and what the future holds.

Listen to episode 17 of the Life Sciences Connect podcast here where we continue with the Future of Public Health series and dive further into the report- Evaluating the role of employers in reducing the public health gap: Improving the health and productivity of employees .

In episode sixteen of the Life Science Connect podcast, we dive into the conversation around our fourth report in our Future of Public Health series; Negating the gap - Preventing ill health and promoting healthy behaviours. Joining our host Karen Taylor, Research Director of the Deloitte UK Centre for Health Solutions, is Dr Karen Kirkham , Chief Medical Officer and Lead Partner for Integration i...

In episode fifteen of the Life Science Connect podcast, we dive into the conversation around our annual R&D Measuring the return from pharmaceutical innovation series report. This report analyses the projected return on investment that biopharma companies can expect to earn from their late-stage pipelines. 

In episode fourteen of the Life Science Connect podcast, we dive into the conversation around planetary health and sustainability in healthcare. Following COP26, it is important that we discuss points around the fundamental risk of climate change and how it impacts our health as well as healthcare delivery and its impact on climate. On this episode of Life Science's Connect podcast, we discuss the...

In our thirteenth episode of the Life Science Connect podcast series, we discuss the findings from The Future of Public Health Series , covered in the overview report: Narrowing the gap: A fairer and more sustainable future for public health. This first instalment of the series summarises the key takeaways from our research of the challenges pre-pandemic, the impact of COVID-19 and the implication...

In our twelfth episode of Life Sciences Connect, our host , Karen Taylor, the Research Director of the Centre for Health Solutions talks to Hanno Ronte, Partner at Monitor Deloitte about consumer research conducted this year on trust in the pharmaceutical industry and explores how COVID-19 has impacted trust, the perception and what role digital can play.  

In our eleventh episode of Life Sciences Connect, we talk to Karen Taylor, Research Director of the Deloitte Centre for Health Solutions who is joined by Thomas Croisier, Consulting Partner, Deloitte France; Deborshi Dutt, Consulting Partner, Deloitte UK and Kristina Schapiro, Consulting Director, Deloitte UK to discuss how companies can use AI to improve drug launches and their commercial models....

In our tenth episode of Life Sciences Connect, we talk to Karen Taylor, Research Director of the Deloitte Centre for Health Solutions who is joined by Naveed Panjwani, Director, Consulting, Deloitte and Kevin Dondarski, Senior Manager, Consulting, Deloitte US to discuss research and development. Visit our Life Sciences Connect Podcast homepage to discover more episodes - https://www2.deloitte.com/...

Our ninth episode of Life Sciences Connect series explores the key trends for the Medtech industry including the rise in consumer organisations entering the space, the evolution from product to service, the changing regulatory landscape, and the acceleration of MedTech in healthcare because of COVID-19. Visit our Life Sciences Connect Podcast homepage to discover more episodes.        

James Gregson, our newly appointed UK Life Sciences and Healthcare leader, joins our episode host Samrina Bhatti, to share his thoughts  on what's next for the industry. James talks about his  leadershipstyle and what makes a good leader as well as his views on digital transformation,collaboration  and developing talent in the Life Sciences and Healthcare industry. Visit our Life Sciences Connect...

What lies ahead for patients, your organisation and your workforce? In this podcast, we explore our predictions for the life sciences and health care industry in 2025, how the pandemic has accelerated industry trends and what this means for you. Our host Karen Taylor, who leads Deloitte Centre for Health Solutions, speaks to  Hanno Ronte, Life Sciences and Healthcare leader Monitor Deloitte, Shiva...

C-suite leaders in pharmaceutical companies increasingly view Real World Evidence (RWE) as strategically important. RWE enables R&D organisations to prioritise their pipeline investments more effectively, better understand underlying causes of disease and identify opportunities for indication expansion and business development. In the sixth episode of Life Sciences Connect, we explore the role of...

Healthcare systems across Europe face rising pressures – particularly the increasing healthcare needs due to growing and ageing populations, multi-morbidity, and public expectations of more personalised and convenient services. Many clinicians are struggling to cope with increasing workloads, and the gap between the supply of resources and the demand for healthcare is widening. Consequently, most...

The Biotech sector is a key player in driving biopharma innovation and developing ground-breaking treatments for patients. Supporting the growth of this sector is vital to ensure that R&D efforts continue, both now and in the future. However, like most industries, this sector faces a complex set of challenges. Over the past six months, the biotech sector has rapidly pivoted to respond to the chall...